Traditional Chinese medicine tea drink composition for treating obesity and hyperlipidemia and application of traditional Chinese medicine tea drink composition

Abstract

The invention relates to a traditional Chinese medicine tea drink composition for treating obesity and hyperlipidemia. The composition is prepared from the following raw material medicines in parts by weight: 4-8 parts of roses, 4-8 parts of lotus leaves, 4-8 parts of pericarpium citri reticulatae, 8-12 parts of cassia seeds, 8-12 parts of raw hawthorn fruits, 8-12 parts of radix salviae miltiorrhizae and 2-6 parts of seville orange flowers. The invention further provides application of the traditional Chinese medicine tea drink composition. The whole formula integrates the functions of promoting digestion, removing food stagnation, promoting diuresis, activating blood, promoting the circulation of qi and relieving depression, treats both symptoms and root causes, is mild in nature, does not hurt healthy qi, and is suitable for people with phlegm-damp constitution, qi stagnation and blood stasis type obesity and hyperlipidemia to drink as tea.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine tea drink composition for treating obesity and hyperlipidemia and application thereof. BACKGROUND

[0002] Hyperlipidemia refers to a class of diseases caused by abnormal metabolism or transport of lipid components in blood. Hyperlipidemia is a systemic disease, also known as dyslipidemia. Hyperlipidemia can cause many serious complications, the most common of which is atherosclerosis. With the development of atherosclerosis, patients can exhibit complications such as coronary heart disease, stroke, and renal artery stenosis. The causes of hyperlipidemia are primary and secondary, and primary hyperlipidemia is often associated with gene mutations and has a clear genetic tendency. Secondary hyperlipidemia is caused by other diseases and known causes of dyslipidemia.

[0003] Chinese patent document CN103349749A discloses a traditional Chinese medicine prescription for treating hyperlipidemia, which comprises, by weight, 15 parts of Rubus chingii Hu, 10 parts of Lycium barbarum, 20 parts of Salvia miltiorrhiza, 15 parts of Cassia senna, 10 parts of Ficus hirta, 15 parts of Crataegus pinnatifida, 15 parts of Polygonum multiflorum, 15 parts of Polygonatum sibiricum, 15 parts of Alisma orientale, 6 parts of Rhus semialata, and 15 parts of Epimedium brevicornu. The prescription is obtained by crushing and packaging, and has the advantages of easy availability of raw materials, low cost, and significant treatment effect.

[0004] Chinese patent document CN118286350A discloses a traditional Chinese medicine for treating hyperlipidemia and hypertension, which comprises an active ingredient comprising, by weight, 6-14 parts of Panax quinquefolium, 5-15 parts of Polygonatum sibiricum, 9-15 parts of Fructus Aurantii, 18-60 parts of Atractylodes macrocephala, 6-20 parts of Radix Rehmanniae Preparata, 15-60 parts of Polygonum multiflorum, 12-30 parts of Semen Plantaginis, 12-30 parts of Pheretima, 15-60 parts of Crataegus pinnatifida, 12-30 parts of Morus alba, and 20-80 parts of Prunella vulgaris. Compared with the prior art, the present application uses natural plants Panax quinquefolium and Prunella vulgaris as the core composition, and combines with various herbs for tonifying qi and spleen, dredging bowels, and resolving turbidity, to achieve the effects of tonifying spleen, benefiting qi, dredging bowels, and resolving turbidity. Through the organic combination of drugs, the three metabolisms are regulated, the effects of reducing hyperlipidemia, protecting blood vessel intima, reducing blood lipid deposition in blood vessel wall, improving myocardial blood supply, diuresis, and relieving blood vessel tension are achieved, thereby improving the clinical symptoms. The safety and effectiveness of the present application have been confirmed by clinical studies, and the present application has good practical clinical application value.

[0005] Such traditional Chinese medicine compositions for treating obesity and hyperlipidemia have the following disadvantages: too many medicinal ingredients, difficult to obtain, and expensive; and the treatment effect is not obvious and the treatment effect is poor. Therefore, there is an urgent need for a traditional Chinese medicine composition for treating obesity and hyperlipidemia, which has obvious effects, fewer medicinal ingredients, is practical, has high compliance, and is safe and effective. SUMMARY

[0006] The present application aims at the deficiencies in the prior art, and provides a traditional Chinese medicine tea drink composition for treating obesity and hyperlipidemia and application thereof.

[0007] In a first aspect, the present application provides a traditional Chinese medicine tea drink composition for treating obesity and hyperlipidemia, which is prepared from the following raw medicinal materials by weight: rose 4-8 parts, lotus leaf 4-8 parts, dried tangerine or orange peel 4-8 parts, cassia seed 8-12 parts, raw hawthorn 8-12 parts, salvia miltiorrhiza 8-12 parts, and daye flower 2-6 parts.

[0008] As a preferred example, the composition is prepared from the following raw medicinal materials by weight: rose 5-7 parts, lotus leaf 5-7 parts, dried tangerine or orange peel 5-7 parts, cassia seed 9-11 parts, raw hawthorn 9-11 parts, salvia miltiorrhiza 9-11 parts, and daye flower 3-5 parts.

[0009] As a preferred example, the composition is prepared from the following raw medicinal materials by weight: rose 6 parts, lotus leaf 6 parts, dried tangerine or orange peel 6 parts, cassia seed 10 parts, raw hawthorn 10 parts, salvia miltiorrhiza 10 parts, and daye flower 4 parts.

[0010] In a second aspect, the present application provides use of the composition in preparation of a medicine for treating obesity and hyperlipidemia.

[0011] As a preferred example, the obesity and hyperlipidemia syndrome type is phlegm turbidity obstruction.

[0012] The present application has the following advantages:

[0013] The present application is mainly used for: invigorating the spleen, promoting digestion, promoting the movement of qi, removing stagnation, promoting blood circulation, and removing dampness and turbidity. It can be used for treating obesity, hyperlipidemia, constipation, and indigestion, etc.

[0014] The treatment principle and the compatibility relationship of monarch, minister, assistant and messenger of the present application are as follows:

[0015] Monarch: hawthorn is the main force for attacking and breaking up.

[0016] Minister: lotus leaf and cassia seed are the excretion channels.

[0017] Assistant and messenger: dried tangerine or orange peel is the core hub, which is responsible for promoting the movement of qi, invigorating the spleen, and removing dampness. Salvia miltiorrhiza is used for strengthening blood circulation, and rose and daye flower are used for regulating emotions and qi movement.

[0018] Monarch raw hawthorn promotes digestion, removes stagnation, promotes blood circulation, and is especially good at digesting and removing stagnation of greasy and fatty food. It can also dilate blood vessels and promote the excretion of cholesterol. It is a medicine with clear lipid-lowering effect confirmed by modern research. It provides the main "digestion" and "removal" power of the present application.

[0019] Minors: Folium Nelumbinis, Cassiae Semen. Folium Nelumbinis clears heat and dampness, and promotes the ascending of clear yang. It can benefit water and dampness, and eliminate phlegm and turbid. Modern research shows that its alkaloids have the effects of reducing fat and losing weight. Its function of ascending clear yang can prevent the sinking of qi due to excessive purgation. Cassiae Semen clears the liver and eyes, and moistens the intestines to promote defecation. It is rich in anthraquinones, which can soften feces and promote excretion, making phlegm, dampness, and fat in the body pass through the stool. It is an important channel for purgation. Folium Nelumbinis assists the monarch herb in reducing dampness and turbidity, and expelling the dampness and turbidity in the body through the water passage. Cassiae Semen assists the monarch herb in purging turbidity by purging the accumulated stagnation and pathogenic heat in the body through the large intestine. The two herbs provide an outlet for pathogenic factors and enhance the effect of the monarch herb in eliminating pathogenic factors and reducing fat.

[0020] Auxiliary herbs: Pericarpium Citri Reticulatae, Salviae Miltiorrhizae Radix et Rhizoma, Rosae Flos, and Daidai Flos. Pericarpium Citri Reticulatae regulates qi and invigorates the spleen, and dries dampness and resolves phlegm. It is a key herb for regulating qi. Qi movement promotes water movement, and smooth qi eliminates phlegm. It regulates the qi movement of the middle energizer, promotes the transportation and transformation of the spleen and stomach, and reduces the formation of phlegm and dampness from the root. Salviae Miltiorrhizae Radix et Rhizoma activates blood and resolves stasis, and cools blood and resolves abscesses. It is as effective as Siwu Decoction. It is good at activating blood and resolving stasis, and can improve microcirculation. It has a good effect on blood viscosity and poor circulation caused by high blood fat. Rosae Flos soothes the liver and relieves depression, and activates blood to stop pain. It has a mild effect on activating blood. Daidai Flos soothes the liver and stomach, and regulates qi and relieves chest stuffiness. It is similar to Rosae Flos, but it focuses more on the qi movement of the middle energizer and spleen and stomach, and is good at relieving abdominal distension, chest stuffiness, and other discomforts.

[0021] Pericarpium Citri Reticulatae mainly regulates qi and invigorates the spleen. On the one hand, it can help digest food (assist Fructus Crataegi), dry dampness (assist Folium Nelumbinis), and prevent qi stagnation. On the other hand, it is warm in nature, which can prevent cold and cool herbs such as Fructus Crataegi and Cassiae Semen from damaging the spleen and stomach, and protect the middle energizer.

[0022] Salviae Miltiorrhizae Radix et Rhizoma: auxiliary herb for activating blood. High blood fat is often accompanied by poor blood circulation. Salviae Miltiorrhizae Radix et Rhizoma activates blood and resolves stasis, which complements the effect of Fructus Crataegi on activating blood, and together improves blood stasis.

[0023] Rosae Flos and Daidai Flos: auxiliary herbs for relieving depression. These two herbs are “flower herbs”, which are light in texture and good at regulating qi. They mainly target the emotional factors (such as stress eating) of obesity and metabolic disorders, and solve the problem from the emotional and qi movement levels by soothing the liver and relieving depression, regulating qi and stomach, which embodies the thought of “preventing disease”.

[0024] The whole prescription integrates digestion, stagnation, dampness reduction, blood activation, qi movement, and depression relief, and treats both the symptoms and the root cause. It is mild in nature and does not harm the healthy qi, and is suitable for people with phlegm-dampness constitution, qi stagnation and blood stasis type obesity and high blood fat to use as a daily tea. DETAILED DESCRIPTION

[0025] The present application will be further described with reference to the following specific embodiments. It is to be understood that these embodiments are merely illustrative of the present application and should not be used to limit the scope of the present application. Furthermore, it is to be understood that any such embodiments are subject to many changes in design, structure, and appearance without departing from the spirit of the present application. Accordingly, the scope of the present application should be gauged by the claims and equivalents thereof.

[0026] Example 1: Tea composition for treating obesity and hyperlipidemia

[0027] Rose 6 parts, Lotus leaf 6 parts, Tangerine peel 6 parts, Cassia seed 10 parts, Crataegus pinnatifida 10 parts, Salvia miltiorrhiza 10 parts, and Daye flower 4 parts.

[0028] Example 2: Tea composition for treating obesity and hyperlipidemia

[0029] Rose 6 parts, Lotus leaf 5 parts, Tangerine peel 7 parts, Cassia seed 8 parts, Crataegus pinnatifida 12 parts, Salvia miltiorrhiza 10 parts, and Daye flower 3 parts.

[0030] Example 3: Tea composition for treating obesity and hyperlipidemia

[0031] Rose 5 parts, Lotus leaf 7 parts, Tangerine peel 4 parts, Cassia seed 12 parts, Crataegus pinnatifida 10 parts, Salvia miltiorrhiza 9 parts, and Daye flower 5 parts.

[0032] Example 4: Tea composition for treating obesity and hyperlipidemia

[0033] Rose 7 parts, Lotus leaf 4 parts, Tangerine peel 8 parts, Cassia seed 10 parts, Crataegus pinnatifida 9 parts, Salvia miltiorrhiza 11 parts, and Daye flower 2 parts.

[0034] Example 5: Tea composition for treating obesity and hyperlipidemia

[0035] Rose 4 parts, Lotus leaf 8 parts, Tangerine peel 6 parts, Cassia seed 9 parts, Crataegus pinnatifida 11 parts, Salvia miltiorrhiza 8 parts, and Daye flower 6 parts.

[0036] Example 6: Tea composition for treating obesity and hyperlipidemia

[0037] Rose 8 parts, Lotus leaf 6 parts, Tangerine peel 5 parts, Cassia seed 11 parts, Crataegus pinnatifida 8 parts, Salvia miltiorrhiza 12 parts, and Daye flower 4 parts.

[0038] Example 7: Tea composition for treating obesity and hyperlipidemia

[0039] Rose 6 parts, Lotus leaf 7 parts, Tangerine peel 4 parts, Cassia seed 12 parts, Crataegus pinnatifida 10 parts, Salvia miltiorrhiza 9 parts, and Daye flower 5 parts.

[0040] Example 8: Tea composition for treating obesity and hyperlipidemia

[0041] Rose 5 parts, lotus leaf 4 parts, dried tangerine or orange peel 8 parts, cassia seed 10 parts, raw hawthorn 9 parts, salvia miltiorrhiza 11 parts, daye flower 2 parts.

[0042] Example 9 Treatment of Obesity and Hyperlipidemia Traditional Chinese Medicine Tea Drink Composition (Nine)

[0043] Rose 7 parts, lotus leaf 8 parts, dried tangerine or orange peel 6 parts, cassia seed 9 parts, raw hawthorn 11 parts, salvia miltiorrhiza 8 parts, daye flower 6 parts.

[0044] Example 10 Treatment of Obesity and Hyperlipidemia Traditional Chinese Medicine Tea Drink Composition (Ten)

[0045] Rose 4 parts, lotus leaf 6 parts, dried tangerine or orange peel 5 parts, cassia seed 11 parts, raw hawthorn 8 parts, salvia miltiorrhiza 12 parts, daye flower 4 parts.

[0046] Example 11 Treatment of Obesity and Hyperlipidemia Traditional Chinese Medicine Tea Drink Composition (Eleven)

[0047] Rose 8 parts, lotus leaf 5 parts, dried tangerine or orange peel 7 parts, cassia seed 8 parts, raw hawthorn 12 parts, salvia miltiorrhiza 10 parts, daye flower 3 parts.

[0048] Example 12 Clinical Efficacy Experiment

[0049] 1. Clinical Data

[0050] 1.1 Case Source

[0051] The observation cases of this topic were all from patients who visited the outpatient department of Chinese general practice and acupuncture injury department of Gonghexinlu Street Community Health Service Center.

[0052] 1.2 Diagnosis Standard

[0053] 1.2.1 Western Medicine Diagnosis Standard

[0054] In accordance with the diagnosis standard of hyperlipidemia in Chinese Blood Lipid Management Guidelines (Primary Version 2024). No lipid-regulating drugs were taken within 2 weeks, daily dietary habits and body weight were maintained, no intense exercise was performed within 24 hours, fasting for 8-12 hours, and blood lipids were detected by venous blood: triglyceride (TG) ≥1.70 mmol / L, or total cholesterol (TC) ≥5.2 mmol / L, or high-density lipoprotein cholesterol (HDL-C) <1.0 mmol / L, or low-density lipoprotein cholesterol (LDL-C) ≥3.4 mmol / L, which can be diagnosed.

[0055] 1.2.2 TCM Syndrome Differentiation Standard

[0056] The syndrome differentiation criteria of phlegm turbidity obstruction syndrome were formulated according to the Guiding Principle of Clinical Study for New Drugs of Traditional Chinese Medicine. (1) Major symptoms: obesity, heavy head as if wrapped, chest distress, vomiting and sputum, limb numbness and heaviness; (2) Minor symptoms: palpitation, insomnia, poor appetite, and less food intake; (3) Tongue and pulse: fat tongue, greasy and slimy fur, and slippery pulse. The syndrome was differentiated when one of the major symptoms and two or more of the minor symptoms were observed, accompanied by tongue and pulse manifestations.

[0057] 1.3 Inclusion Criteria

[0058] (1) meeting the above diagnostic and syndrome differentiation criteria; (2) age: 40-80 years; (3) normal liver and kidney function; (4) clear consciousness and signed informed consent form.

[0059] 1.4 Exclusion Criteria

[0060] (1) pregnant or lactating women; (2) patients with other serious physical and mental diseases; (3) having taken other lipid-lowering drugs or being taking heparin, thyroid hormone or other drugs affecting blood lipid metabolism within the past 2 weeks; (4) drug-induced hyperlipidemia; (5) drug and alcohol dependence.

[0061] 1.5 Exclusion Criteria

[0062] Patients with poor compliance, who stopped treatment halfway; patients who developed serious adverse reactions and could not continue the study;

[0063] Patients who actively gave up treatment due to personal reasons.

[0064] 1.6 Dropouts

[0065] (1) subjects who withdrew from the trial due to adverse reactions, and the researchers should take appropriate measures to address the adverse reactions and record the adverse events in detail;

[0066] (2) subjects who withdrew from the trial due to unsatisfactory treatment effects, and the researchers should take appropriate compensatory treatment measures based on the actual situation;

[0067] (3) after the subjects dropped out, the researchers could contact them through telephone, email or home visits to inquire about the reasons and complete the corresponding evaluation items as much as possible;

[0068] (4) fill in the "treatment completion summary" of the case report form (CRF) to evaluate and analyze the patient's compliance.

[0069] 2. Study Methods

[0070] 2.1 Grouping Method

[0071] 100 cases of hyperlipidemia patients who met the inclusion criteria were randomly divided into observation group and control group. Randomly use simple random method, use SPSS software to generate random numbers, by special person, according to the order of patients to the doctor, through the phone, short message or E-mail immediately get random number for treatment, the test strictly in accordance with the randomized design sequence of patients.

[0072] 2.2 Treatment method

[0073] 50 cases of patients in the control group were treated with western medicine atorvastatin calcium. Atorvastatin calcium tablets (Zhejiang Xindonggang Pharmaceutical Co., Ltd., batch number: GMP H20133127, specification: 10mg / tablet) were taken orally, 1 tablet / time, 1 time / d.

[0074] 50 cases of patients in the observation group were treated with Xiaozhi No. 1 prescription. Xiaozhi No. 1 prescription: rose 6g, lotus leaf 6g, dried tangerine peel 6g, cassia seed 10g, raw hawthorn 10g, danshen 10g, daida flower 4g (provided by Lei Yunshang Chinese medicine shop). Decoction 500ml, 1 day.

[0075] 2.3 Treatment plan

[0076] Both groups were treated for 8 weeks as a course of treatment. During treatment, patients maintained their pre-medication lifestyle and eating habits, and only stopped taking drugs that affected lipid metabolism. Other drugs can continue to be used.

[0077] 2.4 Evaluation method

[0078] The control group was given western medicine atorvastatin calcium tablets for oral treatment, and the observation group was treated with traditional Chinese medicine Xiaozhi No. 1 prescription. The blood lipid levels, TCM syndrome scores and adverse reactions of the two groups were compared before and after 8 weeks of treatment.

[0079] 2.5 Clinical observation index

[0080] 2.5.1 Basic information

[0081] 100 cases of hyperlipidemia patients treated in our center from September 2024 to June 2025 were selected, 50 cases in each group. In the treatment group, 33 cases were male and 17 cases were female, aged 40-80 years, with an average of (55.4±6.2) years; the course of disease was 2-26 years. In the control group, 29 cases were male and 21 cases were female, aged 42-80 years, with an average of (58.4±5.2) years; the course of disease was 2-27 years. There was no significant difference in general data between the two groups (P>0.05), which was comparable.

[0082] 2.5.2 Clinical efficacy evaluation

[0083] (1) Blood lipid levels. Including TC, TG, LDL-C, HDL-C and apolipoprotein (ApoA-I, ApoB).

[0084] (2) TCM syndrome score. According to the TCM syndrome differentiation criteria, the following 12 clinical symptoms consistent with phlegm turbidity obstruction syndrome were selected, quantified and scored as mild, moderate and severe, and recorded once before and after treatment. Main symptoms: obesity, heavy head like wrapping, chest tightness, vomiting sputum, numbness and heaviness of limbs, etc. 5 items; secondary symptoms: palpitation, insomnia, poor appetite, poor appetite, tongue, greasy tongue, and slippery pulse. No symptoms were scored 0, mild symptoms were scored 1, symptoms were obvious but did not affect daily life, workers were scored 2, and symptoms were severe and affected daily life, workers were scored 3.

[0085] Comprehensive efficacy: According to the "Suggestion on the evaluation method of clinical trials of cardiovascular drugs". Clinical control: all blood lipid indicators returned to normal; significant effect: TC decreased by ≥20%, TG decreased by ≥40%, and HDL-C increased by ≥0.26 mmol / L; effective: TC decreased by ≥10% and <20%, TG decreased by ≥20% and <40%, and HDL-C increased by ≥0.104 mmol / L and <0.26 mmol / L; ineffective: did not meet the above standards. Total significant efficiency = (number of cases of clinical control + number of cases of significant effect) / total number of cases x 100%, total effective rate = (clinical control cases + significant cases + effective cases) / total cases x 100%.

[0086] TCM syndrome efficacy was formulated according to "Guiding principles for clinical research of new drugs of traditional Chinese medicine". Clinical control: clinical symptoms and signs disappeared or basically disappeared, and syndrome score decreased by ≥95%; significant effect: clinical symptoms and signs improved significantly, and syndrome score decreased by ≥70% and <95%; effective: clinical symptoms and signs were significantly improved, and syndrome score decreased by ≥30% and <70%; ineffective: clinical symptoms and signs were not significantly improved or aggravated, and syndrome score decreased by <30%. The calculation methods of total significant efficiency and total effective rate are the same as "comprehensive efficacy".

[0087] 2.6 Observation time and follow-up method

[0088] The blood lipid levels, TCM syndrome scores and adverse reactions of the two groups were compared before and 8 weeks after treatment, and the indicators were observed and evaluated.

[0089] 3. Statistical method

[0090] Statistical analysis was performed using SPSS 23.0 statistical software. Measurement data were first tested for normality. Data conforming to normal distribution were expressed as mean ± standard deviation (x ± s), and data not conforming to normal distribution were expressed as median (quartile) [Median (QL-QU)]. Two-sample t test was used for comparison between groups, and paired t test was used for comparison within groups. Non-parametric test was used for comparison between groups for data not conforming to normal distribution. Count data were expressed as percentage, and X2 test was used. P<0.05 was considered statistically significant.

[0091] 4. Results of the study

[0092] 4.1 Comparison of comprehensive efficacy

[0093] The total effective rate was 94.0% (3 cases of clinical control, 12 cases of marked effectiveness, 32 cases of effectiveness, and 3 cases of ineffectiveness) in the observation group, and the total effective rate was 96.0% (20 cases of clinical control, 10 cases of marked effectiveness, 18 cases of effectiveness, and 2 cases of ineffectiveness) in the control group. No statistically significant difference was observed between the two groups (P>0.05).

[0094]

[0095] 4.2 Comparison of TCM syndrome efficacy

[0096] The total effective rate was 92.0% (11 cases of clinical control, 10 cases of marked effectiveness, 25 cases of effectiveness, and 4 cases of ineffectiveness) in the observation group, and the total effective rate was 88.0% (4 cases of clinical control, 11 cases of marked effectiveness, 29 cases of effectiveness, and 6 cases of ineffectiveness) in the control group. The difference was statistically significant (P<0.05).

[0097]

[0098] 4.3 Safety comparison

[0099] No significant changes were observed in liver and kidney function, muscle enzyme detection, and electrocardiogram before and after treatment in the two groups. No clinical discomfort symptoms occurred in the observation group. In the control group, 2 cases (3.3%) had stomach discomfort, and 1 case (2.5%) had decreased appetite, which did not affect medication and disappeared after 3-5 days of continuous medication. No other serious adverse reactions occurred in the two groups.

Claims

1. A traditional Chinese medicine tea composition for treating obesity and hyperlipidemia, characterized in that, The composition is made from the following raw materials in parts by weight: 4-8 parts rose petals, 4-8 parts lotus leaves, 4-8 parts dried tangerine peel, 8-12 parts cassia seeds, 8-12 parts raw hawthorn, 8-12 parts salvia miltiorrhiza, and 2-6 parts bitter orange blossom.

2. The composition according to claim 1, characterized in that, The composition is made from the following raw materials in parts by weight: 5-7 parts rose petals, 5-7 parts lotus leaves, 5-7 parts dried tangerine peel, 9-11 parts cassia seeds, 9-11 parts raw hawthorn, 9-11 parts salvia miltiorrhiza, and 3-5 parts bitter orange blossom.

3. The traditional Chinese medicine composition according to claim 1, characterized in that, The composition is made from the following raw materials in parts by weight: 6 parts rose petals, 6 parts lotus leaves, 6 parts dried tangerine peel, 10 parts cassia seeds, 10 parts raw hawthorn, 10 parts salvia miltiorrhiza, and 4 parts bitter orange blossom.

4. The use of the composition according to any one of claims 1-3 in the preparation of a drug for treating obesity and hyperlipidemia.

5. The application according to claim 4, characterized in that, The aforementioned obesity and hyperlipidemia syndrome is classified as phlegm-dampness obstruction.

Images